Document:

exv10w35

 

Exhibit 10.35

BASE SALARIES FOR EXECUTIVE OFFICERS

     On December 26, 2007, the Compensation Committee of the Board of Directors of Quiksilver, Inc.
(the “Company”) approved new annual base salaries (effective as of November 1, 2007) for the
Company’s named executive officers. The following table sets forth the annual base salary levels
of the Company’s named executive officers for fiscal 2008:

	 	 	 	 	 
	Name and Position	 	Base Salary	 
	Robert B. McKnight, Jr.,

Chief Executive Officer
	 	$	1,075,000	 
	Bernard Mariette,

President
	 	$	900,000	 
	Charles S. Exon,

Executive Vice President, Secretary and General Counsel
	 	$	450,000	 
	Joseph Scirocco,

Executive Vice President, Chief Financial Officer
	 	$	600,000	 
	David H. Morgan,

Executive Vice President, Chief Operating Officer
	 	$	525,000exv4w2

 

Exhibit 4.2

SHAREHOLDERS AGREEMENT

By And Among

Alma Lasers Ltd.

The Shareholders

as defined herein

and

The Investors

as defined herein

Dated
as of March 23, 2006

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page	 
	SECTION I. DEFINITIONS
	 	 	1	 
	1.1. Construction of Terms
	 	 	1	 
	1.2. Terms Not Defined
	 	 	2	 
	1.3. Number of Shares
	 	 	2	 
	1.4. Defined Terms
	 	 	2	 
	 
	 	 	 	 
	SECTION II. REPRESENTATIONS AND WARRANTIES
	 	 	3	 
	2.1. Representations and Warranties of the Shareholders
	 	 	3	 
	2.2. Representations and Warranties of the Investors
	 	 	4	 
	2.3. Representations and Warranties of the Company
	 	 	4	 
	 
	 	 	 	 
	SECTION III. RESTRICTIONS ON TRANSFER; RIGHT OF FIRST REFUSAL;
CO-SALE PROVISIONS; DRAG ALONG
	 	 	5	 
	3.1. Restrictions on Transfer
	 	 	5	 
	3.2. Permitted Transfers
	 	 	5	 
	3.3. Right of Refusal
	 	 	6	 
	3.4. Co-Sale Option of Investors
	 	 	7	 
	3.5. Drag Along
	 	 	9	 
	3.6. Tag Along Right of the Key Shareholders
	 	 	10	 
	3.7. Contemporaneous Transfers
	 	 	10	 
	3.8. Effect of Prohibited Transfers
	 	 	10	 
	3.9. Assignment of Rights
	 	 	10	 
	 
	 	 	 	 
	SECTION IV. RIGHTS TO PURCHASE
	 	 	10	 
	4.1. Right to Participate in Certain Sales of Additional Securities
	 	 	10	 
	4.2. Eligible Shareholders Acceptance
	 	 	11	 
	4.3. Calculation of Pro Rata Allotment
	 	 	11	 
	4.4. Sale to Third Party
	 	 	11	 
	4.5. Exceptions to Pre-Emptive Rights
	 	 	11	 
	4.6. Assignment of Rights
	 	 	12	 
	 
	 	 	 	 
	SECTION V. COVENANTS OF THE COMPANY AND SHAREHOLDERS
	 	 	12	 
	5.1. Financial Statements, Reports, Etc.
	 	 	12	 
	5.2. Inspection, Consultation and Advice
	 	 	13	 
	5.3. Key Person Insurance
	 	 	13	 
	5.4. Directors and Officers’ Insurance; Articles
	 	 	13	 
	5.5. Compensation of Directors
	 	 	13	 
	5.6. Employee Agreements
	 	 	14	 
	5.7. Lock-Up Agreements
	 	 	14	 
	5.8. Indemnification
	 	 	14	 
	 
	 	 	 	 
	SECTION VI. MISCELLANEOUS PROVISIONS
	 	 	15	 
	6.1. Reliance
	 	 	15	 

i

 

	 	 	 	 	 
	 	 	Page	 
	6.2. Legend on Securities
	 	 	15	 
	6.3. Amendment and Waiver; Actions of the Board
	 	 	16	 
	6.4. Notices
	 	 	16	 
	6.5. Headings
	 	 	17	 
	6.6. Counterparts
	 	 	17	 
	6.7. Remedies; Severability
	 	 	17	 
	6.8. Entire Agreement
	 	 	17	 
	6.9. Adjustments
	 	 	18	 
	6.10. Law Governing
	 	 	18	 
	6.11. Successors and Assigns
	 	 	18	 
	6.12. Dispute Resolution
	 	 	18	 
	6.13. Termination
	 	 	18	 
	6.14. Shareholder Lock-Up
	 	 	18	 

	 	 	 	 	 
	EXHIBITS	 	 	 	 
	 
	Exhibit A

	 	-
	 	Form of Joinder Agreement
	 
	Exhibit B

	 	-
	 	Form of Employee Noncompetition, Confidential Information and
Inventions Assignment Agreement

	 	 	 	 	 
	SCHEDULES	 	 	 	 
	 
	Schedule A

	 	-
	 	Shareholders and Investors
	 
	Schedule B

	 	-
	 	Key Employee

ii

 

SHAREHOLDERS AGREEMENT

     THIS
SHAREHOLDERS AGREEMENT (the “Agreement”) is made
as of March 23, 2006,
2006 , by and among Alma Lasers Ltd., a company organized under Israeli law (the “Company”), the
Persons identified on Schedule A hereto as shareholders (the “Shareholders,” and each,
individually, a “Shareholder”) and the Persons identified on Schedule A hereto as investors
(collectively, the “Investors,” and each, individually, an “Investor”) and any other Shareholder
who from time to time becomes party to this Agreement by execution of a Joinder Agreement in
substantially the form attached hereto as Exhibit A (the “Joinder Agreement”). For the purpose of
this Agreement, a Shareholder or an option holder who joins this Agreement pursuant to a Joinder
Agreement shall be included in the term “Shareholder” or “Investor” as specified in such Joinder
Agreement.

     WHEREAS, the Company, certain of the Shareholders and certain of the Investors have entered
into that certain Share Purchase and Redemption Agreement, dated as of February      , 2006 (the
“Purchase Agreement”), whereby (i) such Shareholders have agreed to sell to such Investors, and
such Investors have agreed to purchase, Convertible Preferred Shares (as defined below), and (ii)
the Company has agreed to purchase Ordinary Shares (as defined below) from such Shareholders;

     WHEREAS, on the date hereof, the Company and certain of the Investors are simultaneously
entering into a certain Subordinated Note Purchase Agreement, dated as of the date hereof (the
“Note Purchase Agreement”), whereby such Investors have agreed to purchase Notes (as defined below)
and to be issued Ordinary Shares;

     WHEREAS, the execution and delivery of this Agreement is an inducement and a condition
precedent to the purchase by certain of the Investors of the Convertible Preferred Shares under the
Purchase Agreement and the Notes under the Note Purchase Agreement.

     WHEREAS, the parties hereto desire to agree upon the terms on which the securities of the
Company, now or hereafter outstanding and held by them, will be held, transferred and voted.

     NOW, THEREFORE, in consideration of the premises, as an inducement to the Investors to
consummate the transactions contemplated by the Purchase Agreement and the Note Purchase Agreement,
and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Company, the Shareholders and the Investors hereby covenant and agree with each
other as follows:

SECTION I. DEFINITIONS

     1.1. Construction of Terms. As used herein, the masculine, feminine or neuter gender, and the
singular or plural number, shall be deemed to be or to include the other genders or number, as the
case may be, whenever the context so indicates or requires. Any reference to “day” shall mean a
calendar day unless indicated otherwise.

 

 

     1.2. Terms Not Defined. Capitalized terms used herein and not otherwise defined shall have the
meanings ascribed to them in the Purchase Agreement.

     1.3. Number of Shares. Whenever any provision of this Agreement calls for any calculation
based on a number of shares issued and outstanding or held by a Shareholder or Investor, as
applicable, the number of shares deemed to be issued and outstanding or held by that Shareholder or
Investor, as applicable, unless specifically stated otherwise, shall be the total number of
Ordinary Shares then issued and outstanding and owned by the Shareholder or Investor, as
applicable, plus, without duplication, the total number of Ordinary Shares issuable upon the
conversion of any Convertible Preferred Shares then issued and outstanding and owned by such
Shareholder or Investor, as applicable.

     1.4. Defined Terms. The following capitalized terms, as used in this Agreement, shall have the
meanings set forth below.

     “Affiliate” shall mean, with respect to any Person (as defined below), any other Person which,
directly or indirectly, holds 50% or more of the voting power of or 50% of the voting power of
which is held by, such Person.

     “Articles” shall mean the Company’s Amended and Restated Articles of Association in effect as
of the date hereof, as amended from time to time.

     “Board of Directors” shall mean the board of directors of the Company.

     “Convertible Preferred Shares” shall mean the Convertible Preferred A-l Shares, par value NIS
0.01 per share, of the Company and any other shares issued or issuable with respect thereto
(whether by way of a share dividend or share split or in exchange for or upon conversion of such
shares or otherwise in connection with a combination of shares, recapitalization, merger,
consolidation or other corporate reorganization).

     “Company” shall have the meaning set forth in the preamble to this Agreement and shall include
any successor or successors thereto.

     “Director” shall mean a member of the Board of Directors.

     “Initial Public Offering” shall have the meaning ascribed to the term “IPO” in the Articles,
effective as of the date hereof.

     “Key Shareholder”shall mean any Shareholder which holds (but only for so long as it continues
to hold) not less than 7.5% of the share capital of the Company (determined on a fully diluted
basis).

     “Majority Interest” shall mean Investors holding not less than a majority of the outstanding
Shares held by all Investors, calculated in accordance with Section 1.3 hereof.

     “Notes” shall mean the subordinated notes issued on the date hereof under the Note Purchase
Agreement in the initial principal amount of $15,000,000.

2

 

     “Ordinary Shares” shall mean the Ordinary Shares, par value NIS 0.01 per share, of the Company
and any other common equity securities issued by the Company, and any other shares issued or
issuable with respect thereto (whether by way of a share dividend or share split or in exchange for
or upon conversion of such shares or otherwise in connection with a combination of shares,
recapitalization, merger, consolidation or other corporate reorganization).

     “Person” shall mean any individual, corporation, joint venture, trust, unincorporated
organization, limited liability company, partnership, government and any agency or political
subdivision thereof.

     “Securities” shall mean the Convertible Preferred Shares or the Notes or the Sub Debt Ordinary
Shares.

     “Shares” shall mean, at any time, (i) Ordinary Share, (ii) Convertible Preferred Shares, and
(iii) any other equity securities now or hereafter issued by the Company, together with any options
thereon and any other shares issued or issuable with respect thereto (whether by way of a share
dividend, share split or in exchange for or upon conversion of such shares or otherwise in
connection with a combination of shares, recapitalization, merger, consolidation or other corporate
reorganization). At all times, the number of Shares deemed issued and outstanding or held or to be
voted by any Shareholder or Investor shall be calculated in accordance with Section 1.3.

     “Share Option Plan” means, collectively, the Company’s 2005 Share Option Plan, as may be
amended or revised, and any additional share option plan or similar equity incentive plan as may be
adopted in the future.

     “Sub-Debt Ordinary Shares” shall mean the Ordinary Shares issued to certain of the Investors
under the Note Purchase Agreement, together with any shares or other securities issued with respect
thereto (whether by way of a share dividend or share split or in exchange for or in replacement of
such Sub-Debt Ordinary Shares or otherwise in connection with a combination of shares,
recapitalization, merger, consolidation or other corporate reorganization).

     “Transfer” means any direct or indirect transfer, donation, sale, assignment, pledge,
hypothecation, grant of a security interest in or other disposal or attempted disposal of all or
any portion of a security, any interest or rights in a security, or any rights under this
Agreement. “Transferred” means the accomplishment of a Transfer, and “Transferee” means the
recipient of a Transfer.

SECTION II. REPRESENTATIONS AND WARRANTIES

     2.1. Representations and Warranties of the Shareholders. Each of the Shareholders,
individually and not jointly, hereby represents, warrants and covenants to the Company and the
Investors as follows: (a) such Person has full authority, power and capacity to enter into this
Agreement and perform its obligations hereunder; (b) this Agreement constitutes the valid and
binding obligation of such Person enforceable against it in accordance with its terms, except (i)
as limited by applicable bankruptcy, insolvency, reorganization, moratorium

3

 

and other laws of general application affecting enforcement of creditors’ rights generally,
(ii) as limited by laws relating to the availability of specific performance, injunctive relief, or
other equitable remedies and (iii) to the extent the indemnification provisions may be limited by
applicable laws; and (c) the execution, delivery and performance by such Person of this Agreement
(i) does not and will not violate any laws, rules or regulations of any jurisdiction applicable to
such Person, or require such Person to obtain any approval, consent or waiver of, or to make any
filing with, any other Person that has not been obtained or made and (ii) does not and will not
result in a breach of, constitute a default under, accelerate any obligation under or give rise to
a right of termination of any indenture or loan or credit agreement or any other material
agreement, contract, instrument, mortgage, lien, lease, permit, authorization, order, writ,
judgment, injunction, decree, determination or arbitration award to which such Person is a party or
by which the property of such Person is bound or affected, or result in the creation or imposition
of any mortgage, pledge, lien, security interest or other charge or encumbrance on any of the
assets or properties of such Person.

     2.2. Representations and Warranties of the Investors. Each of the Investors, individually and
not jointly, hereby represents, warrants and covenants to the Company and the Shareholders as
follows: (a) such Investor has full authority, power and capacity to enter into this Agreement and
perform its obligations hereunder; (b) this Agreement constitutes the valid and binding obligation
of such Investor enforceable against it in accordance with its terms, except (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief, or other equitable remedies and (iii) to
the extent the indemnification provisions may be limited by applicable laws; and (c) the execution,
delivery and performance by such Investor of this Agreement (i) does not and will not violate any
laws, rules or regulations of any jurisdiction applicable to such Investor, or require such
Investor to obtain any approval, consent or waiver of, or to make any filing with, any Person that
has not been obtained or made and (ii) does not and will not result in a breach of, constitute a
default under, accelerate any obligation under or give rise to a right of termination of any
indenture or loan or credit agreement or any other material agreement, contract, instrument,
mortgage, lien, lease, permit, authorization, order, writ, judgment, injunction, decree,
determination or arbitration award to which such Investor is a party or by which the property of
such Investor is bound or affected, or result in the creation or imposition of any mortgage,
pledge, lien, security interest or other charge or encumbrance on any of the assets or properties
of such Investor.

     2.3. Representations and Warranties of the Company. The Company hereby represents, warrants
and covenants to the Investors and the Shareholders as follows: (a) the Company has full authority,
power and capacity to enter into this Agreement and perform its obligations hereunder; (b) this
Agreement constitutes the valid and binding obligation of the Company enforceable against it in
accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies, and (iii) to the extent the
indemnification provisions may be limited by applicable federal or state securities laws; and (c)
the execution, delivery and performance by the Company of this Agreement (i) does not and will not
violate any laws, rules or regulations applicable to the Company, or

4

 

require the Company to obtain any approval, consent or waiver of, or to make any filing with,
any Person that has not been obtained or made and (ii) does not and will not result in a breach of,
constitute a default under, accelerate any obligation under or give rise to a right of termination
of any indenture or loan or credit agreement or any other material agreement, contract, instrument,
mortgage, lien, lease, permit, authorization, order, writ, judgment, injunction, decree,
determination or arbitration award to which the Company is a party or by which the property of the
Company is bound or affected, or result in the creation or imposition of any mortgage, pledge,
lien, security interest or other charge or encumbrance on any of the assets or properties of the
Company.

SECTION III. RESTRICTIONS ON TRANSFER; RIGHT OF FIRST REFUSAL; CO-SALE PROVISIONS; DRAG ALONG

     3.1. Restrictions on Transfer.

          (a) Each Shareholder and Investor agrees that such Shareholder or Investor (as applicable)
will not, without the prior written consent of a Majority Interest (in the case of a Shareholder)
or a majority in interest of the Key Shareholders (in the case of an Investor), Transfer all or any
portion of the Shares now owned or hereafter acquired by such Shareholder or Investor (as
applicable), except in connection with, and strictly in compliance with, the provisions of this
Section III.

          (b) Notwithstanding anything in this Section III to contrary, any Transfer by a Shareholder
holding one percent (1%) or more of the share capital of the Company (determined on a fully diluted
basis) shall require consent of a Majority Interest.

     3.2. Permitted Transfers. Notwithstanding anything herein to the contrary, the provisions of
Sections 3.3 and 3.4 shall not apply to either of the Transfers listed below in subsections (a) and
(c); provided that, in the case of any such Transfer, the Transferee shall have entered into a
Joinder Agreement in substantially the form attached hereto as Exhibit A providing that all Shares
so Transferred shall continue to be subject to all provisions of this Agreement as if such Shares
were still held by such Shareholder or Investor (as applicable), except that no further Transfer
shall thereafter be permitted hereunder except in compliance with Sections 3.3 and 3.4:

          (a) Transfers by any Shareholder or Investor which is a natural person to the children or
siblings of such Shareholder or to a trust or family limited partnership for the exclusive benefit
of any such children or siblings;

          (b) Transfers upon the death of any Shareholder or Investor (as applicable) which is a natural
person to such Shareholder’s or Investor’s heirs, executors or administrators or to a trust under
such Shareholder’s or Investor’s will, or Transfers between such Shareholder or Investor (as
applicable) and such Shareholder’s or Investor’s (as applicable) guardian or conservator; and

5

 

          (c) Transfers by any Shareholder or Investor which is a legal entity to any of its Affiliates.

Notwithstanding anything to the contrary in this Agreement, if a Transferee that is a party to a
Transfer described in this Section 3.2 (a “Permitted Transferee”) fails to execute a Joinder
Agreement, such Transferee shall take any Shares so Transferred subject to all provisions of this
Agreement as if such Shares were still held by the Shareholder or Investor making such Transfer,
whether or not they so agree in writing.

     3.3. Right of Refusal. In the event that any of the Shareholders entertains a bona fide offer
(a “Transaction Offer”) from any other Person (a “Buyer”) to purchase all or any portion of the
Shares held by such Shareholder, such Shareholder (a “Transferring Shareholder”) may, subject to
the provisions of Section 3.4 hereof, Transfer such Shares pursuant to and in accordance with the
following provisions of this Section 3.3:

          (a) Offer Notice. The Transferring Shareholder shall cause the Transaction Offer and all of
the terms thereof to be reduced to writing and shall promptly notify the Company, each of the
Investors and each Key Shareholder of such Transferring Shareholder’s desire to effect the
Transaction Offer and otherwise comply with the provisions of this Section 3.3 and, if applicable,
Section 3.4 (such notice, the “Offer Notice”). The Offer Notice shall constitute an irrevocable
offer to sell all (or any portion) of the Shares which are the subject of the Transaction Offer
(the “Offered Shares”) to the Investors and Key Shareholders (each, an “Eligible Shareholder”), on
the basis described below, at a purchase price equal to the price contained in, and on the same
terms and conditions as, the Transaction Offer. The Offer Notice shall be accompanied by a true
copy of the Transaction Offer (which shall identify the Buyer and all relevant information in
connection therewith).

          (b) Eligible Shareholders’ Option. At any time within thirty (30) days after receipt by the
Eligible Shareholders of the Offer Notice (the “Eligible Shareholder Option Period”), each Eligible
Shareholder or any of its Affiliates, may elect to accept the offer to purchase with respect to any
or all of the Offered Shares and shall give written notice of such election (the “Eligible
Shareholder Acceptance Notice”) to the Transferring Shareholder and each other Eligible Shareholder
within the Eligible Shareholder Option Period, which notice shall indicate the maximum number of
Offered Shares that the Eligible Shareholder is willing to purchase, including the number of
Offered Shares it would purchase if one or more other Eligible Shareholders do not elect to
purchase their Pro Rata Fractions (as defined in paragraph (c) below). An Eligible Shareholder
Acceptance Notice shall constitute a valid, legally binding and enforceable agreement for the sale
and purchase of the Offered Shares covered by such Eligible Shareholder Acceptance Notice. The
closing for the purchase of Offered Shares by the Eligible Shareholders or any of their Affiliates
under this Section 3.3(b) shall take place within thirty (30) days following the expiration of the
Eligible Shareholder Option Period at the offices of the Company or on such other date or at such
other place as may be agreed to by the Transferring Shareholder and such Eligible Shareholders or
Affiliates. The Transferring Shareholder shall notify the Eligible Shareholders promptly if any
Eligible Shareholder or Affiliate fails to offer to purchase all of its Pro Rata Fraction (as
defined below).

6

 

          (c) Allocation of Offered Shares among Eligible Shareholders. Upon the expiration of the
Eligible Shareholder Option Period, the number of Offered Shares to be purchased by each Eligible
Shareholder or any of its Affiliates shall be determined as follows: (i) first, there shall be
allocated to each Eligible Shareholder electing to purchase a number of Offered Shares equal to the
lesser of (A) the number of Offered Shares as to which such Eligible Shareholder accepted the offer
to purchase, as set forth in its respective Eligible Shareholder Acceptance Notice and (B) such
Eligible Shareholder’s Pro Rata Fraction (as defined below), and (ii) second, the balance, if any,
not allocated under clause (i) above, shall be allocated to those Eligible Shareholders who within
the Eligible Shareholder Option Period delivered an Eligible Shareholder Acceptance Notice that
accepted the offer to purchase with respect to a number of Offered Shares that exceeded their
respective Pro Rata Fractions, in each case on a pro rata basis in proportion to the number of
Shares held by each such Eligible Shareholder up to the amount of such excess. As used herein, an
Eligible Shareholder’s “Pro Rata Fraction” shall be equal to the product obtained by multiplying
the total number of Offered Shares by a fraction, the numerator of which is the total number of
Shares owned by such Eligible Shareholder, and the denominator of which is the total number of
Shares held by all Eligible Shareholders, in each case calculated as of the date of the Offer
Notice.

          (d) Valuation of Property. If all or any portion of the purchase price set forth in the Offer
Notice consists of consideration other than cash or cash equivalents, the Transferring Shareholder,
the Company and a Majority Interest shall mutually determine the fair market value of such
consideration, reasonably and in good faith, and the Eligible Shareholders may effect their
purchase under this Section 3.3 by payment in cash or cash equivalents of the amount of such fair
market value.

          (e) Sale to Third Party. If the Eligible Shareholders do not elect to exercise the rights to
purchase under this Section 3.3 with respect to all of the Offered Shares proposed to be sold, the
Transferring Shareholder may (i) revoke its Offer Notice and sell all the Offered Shares, or (ii)
sell the remaining balance of such Offered Shares to the Buyer, on the terms and conditions set
forth in the Offer Notice, subject to the provisions of Section 3.4. If the Transferring
Shareholder’s sale to a Buyer is not consummated in accordance with the terms of Section 3.4, the
Transaction Offer shall be deemed to lapse, and any Transfers of
Shares pursuant to such Transaction Offer shall be in violation of the provisions of this Agreement unless the Transferring
Shareholder sends a new Offer Notice and once again complies with the provisions of this Section
3.3 with respect to such Transaction Offer.

     3.4. Co-Sale Option of Investors. If a Transferring Shareholder, provides an Offer Notice to
sell the Offered Shares and the Eligible Stockholders do not elect to exercise the rights to
purchase under Section 3.3 with respect to all of the Offered Shares proposed to be sold, the
Transferring Shareholder may (i) revoke its Offer Notice and sell all the Offered Shares; or (ii)
sell the remaining balance of such Offered Shares to the Buyer, on the terms and conditions set
forth in the Offer Notice, subject to the provisions of this Section 3.4 that are set forth below:

          (a) Co-Sale Notice. As soon as practicable following the expiration of the Eligible
Shareholder Option Period, and in no event later than five (5) days thereafter, the Transferring
Shareholder shall provide notice to each of the Eligible Shareholders (the “Co-Sale Notice”) of its
right to participate in the Transaction Offer on a pro rata basis with the

7

 

Transferring Shareholder (the “Co-Sale Option”). To the extent one or more Eligible Shareholders
exercise their Co-Sale Option in accordance with this Section 3.4, the number of Shares that the
Transferring Shareholder may Transfer pursuant to the Transaction Offer shall be correspondingly
reduced.

          (b) Eligible Shareholder Acceptance. Each of the Eligible Shareholders shall have the right to
exercise its Co-Sale Option by giving written notice (the “Co-Sale Acceptance Notice”) to the
Transferring Shareholder within ten (10) days after receipt by such Eligible Shareholder of the
Co-Sale Notice (the “Co-Sale Election Period”). Each Co-Sale Acceptance Notice shall set forth the
maximum number of Shares subject thereto which the Eligible Shareholder wishes to sell, including
the number of Shares it would sell if one or more other Eligible Shareholders do not elect to
participate in the sale on the terms and conditions stated in the Offer Notice. Any Eligible
Shareholder holding Convertible Preferred Shares shall be permitted to sell to the relevant Buyer
in connection with any exercise of the Co-Sale Option Ordinary Shares acquired upon conversion of
such Convertible Preferred Shares.

          (c) Allocation of Shares. Each Eligible Shareholder shall have the right to sell pursuant to
the Transaction Offer that portion of its Shares which is equal to or less than the product
obtained by multiplying the total number of Shares available for sale to the Buyer subject to the
Transaction Offer by a fraction, the numerator of which is the total number of Shares owned by such
Eligible Shareholder and the denominator of which is the total number of Shares held by all
Eligible Shareholders and the Transferring Shareholder, in each case, as of the date of the Offer
Notice, subject to increase as hereinafter provided. If any Eligible Shareholder does not elect to
sell the full amount of such Shares which such Eligible Shareholder is entitled to sell pursuant
to this Section 3.4, then any other Eligible Shareholders who have elected to sell Shares shall
have the right to sell, on a pro rata basis (based on the number of Shares held by each such
Eligible Shareholder) with any other Eligible Shareholders and up to the maximum number of Shares
stated in each such Eligible Shareholder’s Co-Sale Acceptance Notice, any Shares not elected to be
sold by such Eligible Shareholder.

          (d) Co-Sale Closing. Within ten (10) calendar days after the end of the Co-Sale Election
Period, the Transferring Shareholder shall promptly notify each participating Eligible Shareholder
of the number of Shares held by such Eligible Shareholder that will be included in the sale and the
date on which the Transaction Offer will be consummated, which shall be no later than the later of
(i) ninety (90) calendar days after the end of the Co-Sale Election Period and (ii) the date of the
satisfaction of any governmental approval or filing requirements. Each participating Eligible
Shareholder may effect its participation in any Transaction Offer hereunder by delivering to the
Buyer, or to the Transferring Shareholder for delivery to the Buyer, one or more instruments or
certificates, properly endorsed for transfer, representing the Shares it elects to sell pursuant
thereto. At the time of consummation of the Transaction Offer, the Transferring Shareholder shall
cause the Buyer to remit directly to each participating Eligible Shareholder that portion of the
sale proceeds to which the participating Eligible Shareholder is entitled by reason of its
participation in the Transaction Offer. No Shares may be purchased by the Buyer from the
Transferring Shareholder unless the Buyer simultaneously purchases from the participating Eligible
Shareholders all of the Shares that they have elected to sell pursuant to this Section 3.4.

8

 

          (e) Sale to Third Party. Any Shares held by a Transferring Shareholder that are the subject of
a Transaction Offer and that the Transferring Shareholder desires to Transfer to a Buyer in
compliance with this Section 3.4, may be sold to such Buyer only during the period specified in
Section 3.4(d) and only on terms no more favorable to the Transferring Shareholder than those
contained in the Offer Notice. Promptly after such Transfer, the Transferring Shareholder shall
notify the Company and the Eligible Shareholders of the consummation thereof and shall furnish such
evidence of the completion and time of completion of the Transfer and of the terms thereof as may
be reasonably requested by the Company. Prior to the effectiveness of any Transfer to a Buyer
hereunder, such Buyer shall have entered into a Joinder Agreement in substantially the form
attached hereto as Exhibit A. and such Buyer shall have all the rights and obligations hereunder as
if such Buyer were a Shareholder. In the event that the Transaction Offer is not consummated within
the period required by this Section 3.4 or the Buyer fails timely to remit to each participating
Eligible Shareholder its respective portion of the sale proceeds, the Transaction Offer shall be
deemed to lapse, and any Transfer of Shares pursuant to such Transaction Offer shall be in
violation of the provisions of this Agreement unless the Transferring Shareholder sends a new Offer
Notice with respect to such Offered Shares and once again complies with the provisions of Section
3.3 and Section 3.4 with respect to such Transaction Offer.

     3.5. Drag Along.

          (a) In the event of a Sale Event (as defined below), each Shareholder and Investor shall, upon
the written request of a Majority Interest (i) sell, transfer and deliver, or cause to be sold,
transferred and delivered, to the Third Party Buyer all of its Shares on the same terms applicable
to the Majority Interest (with due reflection of the relative rights and preferences of the Shares
as provided in the Articles), and/or (ii) execute and deliver such instruments of conveyance and
transfer and take such other action, including voting such Shares in favor of any Sale Event
proposed by the Majority Interest and executing any purchase agreements, merger agreements,
indemnity agreements, escrow agreements or related documents, as such Majority Interest and the
Third Party Buyer may reasonably require in order to carry out the terms and provisions of this
Section 3.5 (the “Drag-Along Right”).

          (b) For purposes of this Section 3.5:

     (i) a “Sale Event” shall mean a bona fide negotiated transaction with a third party in
which the Majority Interest have determined (A)  to sell their Shares in a transaction that
will result in a majority of the voting power of the Company immediately prior to such
transaction being transferred to such third party, (B) to sell or otherwise dispose of all
or substantially all of the assets of the Company, or (C) to cause the Company to merge
with or into, or consolidate with, any non-Affiliate(s) of the Company; and

     (ii) A “Third Party Buyer” shall mean the buyer or buyers in Section 3.5(b)(i)(A) or
(B), and the surviving entity in Section 3.5(b)(i)(C).

          (c) Not less than fifteen (15) days prior to the date proposed for the closing of any Sale
Event, the Majority Interest shall give notice to each of the Shareholders setting forth in

9

 

reasonable detail the name or names of the Third Party Buyer, the terms and conditions of the
Sale Event, including the purchase price, and the proposed closing date. In furtherance of the
provisions of this Section 3.5, each of the Shareholders hereby (i) irrevocably appoints the
designee of the Majority Interest as its agent and attorney-in-fact (the “Agent”) (with full power
of substitution) to execute all agreements, instruments and certificates and take all actions
necessary or desirable to effectuate any sale hereunder; and (ii) grants to the Agent a proxy to
vote the shares held by the Shareholders in favor of any Sale Event hereunder.

     3.6. Tag Along Right of the Key Shareholders. In the event of a Sale Event, the holders of a
majority of the Shares held by all Key Shareholders shall, in the event that a Majority Interest
does not exercise the Drag-Along Right set forth in Section 3.5 above, have the right to require
the Investors to include the Key Shareholders’ Shares in the Sale Event on the same terms and
conditions, as the Shares held by the Investors (the “Tag-Along Right”); provided that the Key
Shareholders undertake all obligations undertaken by the Investors in connection with such Sale
Event, including without limitation, all indemnification and escrow obligations.

     3.7. Contemporaneous Transfers. If two or more Shareholders or Investors propose concurrent
Transfers that are subject to this Section III, then the relevant provisions of Section 3.3 and
Section 3.4, as applicable, shall apply separately to each such proposed Transfer.

     3.8. Effect of Prohibited Transfers. If any Transfer by any Shareholder or Investor is made
or attempted contrary to the provisions of this Agreement, (a) such purported Transfer shall be
void ab initio, (b) the Company and the other parties hereto shall have, in addition to any other
legal or equitable remedies which they may have, the right to enforce the provisions of this
Agreement by actions for specific performance (to the extent permitted by law), and (c) the Company
shall have the right to refuse to recognize any Transferee of such Shareholder or Investor for any
purpose.

     3.9. Assignment of Rights. Subject to Sections 3.6 and 6.11 hereof, each Investor shall have
the right to assign its rights under this Section III to any Transferee of such Investor’s
Securities, and any such Transferee shall be deemed within the definition of an “Investor” for
purposes of this Section III.

SECTION IV. RIGHTS TO PURCHASE

     4.1. Right to Participate in Certain Sales of Additional Securities. The Company agrees that
it will not sell or issue or agree to sell or issue: (a) any shares of the Company, (b) any
securities convertible into or exercisable or exchangeable for share capital of the Company, or (c)
any options, warrants or rights carrying any rights to purchase share capital of the Company,
unless the Company first submits a written notice to each Eligible Shareholder identifying the
terms of the proposed sale (including price, number or aggregate principal amount of securities and
all other material terms), and offers to each Eligible Shareholder, the opportunity to purchase its
Pro Rata Allotment (as hereinafter defined) of the securities (subject to increase for
over-allotment if some Eligible Shareholders do not fully exercise their rights) on terms and
conditions, including price, not less favorable than those on which the Company

10

 

proposes to sell such securities to a third party or parties (a “Pre-Emptive Right Notice”).
The Company’s offer pursuant to this Section 4.1 shall remain open and irrevocable for a period of
ten (10) days following receipt by the Eligible Shareholders of such written notice.

     4.2. Eligible Shareholders Acceptance. Each of the Eligible Shareholders shall have the right
to purchase its Pro Rata Allotment by giving written notice of such intent to participate (the
“Pre-emptive Right Acceptance Notice”) to the Company within ten (10) days after receipt by such
Eligible Shareholders of the Pre-Emptive Right Notice (the “Pre-Emptive Right Acceptance Election
Period”). Each Pre-Emptive Right Acceptance Notice shall set forth the maximum number of Shares
subject thereto which the Eligible Shareholder wishes to buy, including the number of Shares it
would buy if one or more other Eligible Shareholders do not elect to participate in the sale on the
terms and conditions stated in the Pre-Emptive Right Notice.

     4.3. Calculation of Pro Rata Allotment. Each Eligible Shareholders “Pro Rata Allotment” of
such securities shall be based on the ratio which the number of Shares owned by such Eligible
Shareholder bears to all of the issued and outstanding Shares as of the date of such written offer.
If one or more Eligible Shareholders do not elect to purchase their respective Pro Rata Allotment,
each of the electing Eligible Shareholders may purchase such shares of each such non-electing
Eligible Shareholder’s allotments (taking into account the maximum amount each is wishing to
purchase) on a pro rata basis, based upon the relative holdings of Shares of each of the electing
Eligible Shareholders in the case of over-subscription.

     4.4. Sale to Third Party. Any securities so offered that are not purchased by the Eligible
Shareholders pursuant to the offer set forth in Section 4.1 above may be sold by the Company, but
only on terms and conditions not more favorable to the purchaser than those set forth in the notice
to Eligible Shareholders, at any time after five (5) days but within sixty (60) days following the
termination of the above-referenced 10-day period, but may not be sold to any other Person or on
terms and conditions, including price, that are more favorable to the purchaser than those set
forth in such offer or after such 60-day period without renewed compliance with this Section IV.

     4.5. Exceptions to Pre-Emptive Rights. Notwithstanding the foregoing, the rights granted to
Eligible Shareholders under this Section IV shall be inapplicable with respect to (i) the issuance
of up to an aggregate of 143,013,000 Ordinary Shares or options therefore, or such other higher
number approved by the Board (as appropriately adjusted for any share split, combination,
reorganization, recapitalization, reclassification, share distribution, share dividend or similar
event) issued or issuable in connection with, or upon the exercise of, options or other awards
granted or to be granted to employees, officers or directors of the Company pursuant to the
Company’s Share Option Plan, including Ordinary Shares issued in replacement of such Ordinary Share
repurchased or issuable upon the exercise of any options to purchase such Ordinary Share, to the
extent permitted under the Share Option Plan, (ii) securities issued as a result of any share
split, share dividend, reclassification or reorganization or similar event with respect to the
Shares, (iii) Ordinary Shares issued upon conversion of, or as a dividend on, the Convertible
Preferred Shares, (iv) Ordinary Shares issued upon the exercise of the Warrants (as defined in the
Purchase Agreement), (v) securities issued in connection with the acquisition of another
corporation, business entity or line of business of another business entity by the

11

 

Company by merger, consolidation, purchase of all or substantially all of the assets, or other
reorganization as a result of which the Company owns not less than fifty percent (50%) of the
voting power of such corporation, (vi) Ordinary Shares issued in the Initial Public Offering, or
(vii) any other securities issued with the approval of a Majority Interest.

     4.6. Assignment of Rights. Subject to Sections 6.11 and 3.6 hereof, each Investor shall have
the right to assign its rights under this Section IV to any Transferee of such Investor’s
Securities, and shall further have the right to assign and transfer such Investor’s right to accept
any particular offer under Section 4.1 hereof, and any such Transferee shall be treated as Investor
for purposes of this Section IV.

SECTION V. COVENANTS OF THE COMPANY AND SHAREHOLDERS

     The Company covenants and agrees with each of the Eligible Shareholders that:

     5.1. Financial Statements, Reports, Etc. The Company shall furnish to each Eligible
Shareholder the following reports:

          (a) Annual Financial Statements. Within ninety (90) days after the end of each fiscal year of
the Company, a consolidated balance sheet of the Company and its subsidiaries as of the end of such
fiscal year and the related consolidated statements of income, shareholders’ equity and cash flows
for the fiscal year then ended, prepared in accordance with generally accepted accounting
principles and certified by a firm of independent public accountants of recognized national
standing selected by the Board of Directors of the Company;

          (b) Quarterly Financial Statements. Within forty-five (45) days after the end of each fiscal
quarter of the Company, a consolidated balance sheet of the Company and its subsidiaries and the
related consolidated statements of income, shareholders’ equity and cash flows for the fiscal
quarter then ended, unaudited but prepared in accordance with generally accepted accounting
principles and certified by the chief financial officer of the Company, such consolidated balance
sheet to be as of the end of such quarter and such consolidated statements of income, shareholders’
equity and cash flows to be for such quarter and for the period from the beginning of the fiscal
year to the end of such quarter, in each case, with comparative statements for the prior fiscal
year; and

          (c) Monthly Financial Statements. Commencing as soon as practicable after the date hereof,
within twenty-five (25) days after the end of each month in each fiscal year (other than the last
month in each fiscal year), a consolidated balance sheet of the Company and its subsidiaries and
the related consolidated statements of income, shareholders’ equity and cash flows for the monthly
period then ended, unaudited but prepared in accordance with generally accepted accounting
principles and certified by the chief financial officer of the Company, such consolidated balance
sheet to be as of the end of such month and such consolidated statements of income, shareholders’
equity and cash flows to be for such month and for the period from the beginning of the fiscal year
to the end of such month, in each case with comparative statements for the prior fiscal year;

12

 

          (d) Budget. No later than thirty (30) days prior to the start of each fiscal year,
consolidated capital and operating expense budgets, cash flow projections and income and loss
projections for the Company and its subsidiaries in respect of such fiscal year, all itemized in
reasonable detail and prepared on a monthly basis, and, promptly after preparation, any revisions to any of the foregoing;

          (e) Accountant’s Letters. Promptly following receipt by the Company, each audit response
letter, accountant’s management letter and other written report submitted to the Company by its
independent public accountants in connection with an annual or interim audit of the books of the
Company or any of its subsidiaries;

          (f) Notices. Promptly after the commencement thereof, notice of all actions, suits, claims,
proceedings, investigations and inquiries that could materially and adversely affect the Company or
any of its subsidiaries; and

          (g) Other Information. Promptly, from time to time, such other information regarding the
business, prospects, financial condition, operations, property or affairs of the Company and its
subsidiaries as such Investor reasonably may request.

     5.2. Inspection, Consultation and Advice. The Company shall permit and cause each of its
subsidiaries, if any, to permit each Investor and such persons as each Investor may designate, at
such Investor’s expense, to visit and inspect any of the properties of the Company and its
subsidiaries, examine their books and take copies and extracts therefrom, discuss the affairs,
finances and accounts of the Company and its subsidiaries with their officers, employees and public
accountants (and the Company hereby authorizes said accountants to discuss with such Investor and
such designees such affairs, finances and accounts), and consult with and advise the management of
the Company and its subsidiaries as to their affairs, finances and accounts, all at reasonable
times and upon reasonable notice during normal business hours. The foregoing shall be in addition
to, and not in lieu of, the Investors’ rights under applicable law.

     5.3. Key Person Insurance. The Company shall obtain as of the date of the Closing and in any
event no later than thirty (30) days after the date of the Closing, and maintain, “key person” term
life insurance policies of at least $[2,000,000] on the life of Mr. Ziv Karni which shall name the
Company as beneficiary.

     5.4. Directors and Officers’ Insurance; Articles. The Company shall, as promptly as
practicable following the date hereof, obtain and maintain directors and officers’ liability
insurance coverage on terms satisfactory to the Investor Nominees of at least $5,000,000 per
occurrence, to the fullest extent permitted by law. The Company shall at all times maintain
provisions in its Articles indemnifying all directors against liability and absolving all directors
from liability to the Company and its Shareholders to the maximum extent permitted under applicable
laws.

     5.5. Compensation of Directors. Subject to the Company’s traveling policy, the Company shall
pay or promptly reimburse in full all of its Directors for all of their reasonable out-of-pocket
expenses incurred in attending each meeting of the Board of Directors or any committee thereof.

13

 

     5.6. Employee Agreements. The Company shall obtain, and shall cause its subsidiaries, if any,
to obtain, a Noncompetition, Confidential Information and Inventions Assignment Agreement in
substantially the form of Exhibit B attached hereto from all future officers and employees and any
consultants who have or will have access to confidential information of the Company or any of its
subsidiaries, upon commencement of their employment or consulting arrangement with the Company or
any of its subsidiaries.

     5.7. Lock-Up Agreements. The Company will obtain agreements in writing from each future holder
of shares or options of the Company as a condition to any issuance of shares or grant of options,
agreeing not to directly or indirectly offer, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant for the
sale of or otherwise dispose of or transfer any shares of the Company in connection with any public
offering of the Company’s share capital without the written consent of the underwriters engaged by
the Company for such offering, consistent with the provisions of Section 6.14 of this Agreement.

     5.8. Indemnification.

          (a) Subject to applicable law, without limitation of any other provision of this Agreement,
the Company, on its own behalf and on behalf of its successors and assigns, agrees to defend,
indemnify and hold each Investor, its respective Affiliates and direct and indirect partners
(including partners of partners and Shareholders and members of partners), members, Shareholders,
directors, officers, employees and agents and each person who controls any of them within the
meaning of Section 15 of the Unites States Securities Act of 1933 (as amended) or Section 20 of the
United Stated Exchange Act of 1934 (as amended) (collectively, the
“Investor Indemnified Parties” and, individually, an “Investor Indemnified Party”) harmless
from and against any and all damages, liabilities, losses, taxes, fines, penalties, diminution in
value, reasonable costs and expenses (including, without limitation, reasonable fees of a single
counsel representing all the Investor Indemnified Parties or, if the representations of all the
Investor Identified Parties by the same counsel would be inappropriate under applicable standards
of professional conduct, then as many counsel as may be needed under such standards of professional
conduct to represent all of the Investor Indemnified Parties), as the same are incurred, of any
kind or nature whatsoever (whether or not arising out of third-party claims and including all
amounts paid in investigation, defense or settlement of the foregoing and consequential damages)
(“Losses”) sustained or suffered by any such Investor Indemnified Party, which may be based upon,
relating to, arising out of, or by reason of any third party or governmental claims relating in any
way to such Investor Indemnified Party’s status as a security holder, creditor, director, agent,
representative or controlling person of the Company or otherwise relating to such Investor
Indemnified Party’s involvement with the Company, including, without limitation, in connection with
any third party or governmental action or claim relating to any action taken or omitted to be taken
or alleged to have been taken or omitted to have been taken by any Investor Indemnified Party as
security holder, director, agent, representative or controlling person of the Company or otherwise,
alleging so-called control person liability or securities law liability; provided, however, that
the Company will not be liable to any Investor Indemnified Party to the extent that such Losses
arise from and are based on (A) an untrue statement or omission or alleged untrue statement or
omission in a registration statement or prospectus which is made in reliance on and in conformity
with written information

14

 

furnished to the Company by or on behalf of such Investor Indemnified Party, (B) conduct by
such Investor Indemnified Party which is found to constitute fraud or willful misconduct in a
non-appealable, final judgment, or (C) any claims by the Company or its Shareholders.

          (b) If the indemnification provided for in Section 5.8(a) above for any reason is held by a
court of competent jurisdiction to be unavailable to an Investor Indemnified Party in respect of
any Losses referred to therein, then the Company, in lieu of indemnifying such Investor Indemnified
Party thereunder, shall contribute to the amount paid or payable by such Investor Indemnified Party
as a result of such Losses (i) in such proportion as is appropriate to reflect the relative
benefits received by the Company and the Investors, or (ii) if the allocation provided by clause
(i) above is not permitted by applicable law in such proportion as is appropriate to reflect not
only the relative benefits referred to in clause (i) above but also the relative fault of the
Company and the Investors in connection with the action or inaction which resulted in such Losses,
as well as any other relevant equitable considerations. The relative fault of the Company and the
Investors shall be determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company and the Investors and the parties’ relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission.

          (c) Each of the Company and the Investors agrees that it would not be just or equitable if
contribution pursuant to Section 5.8(b) were determined by pro rata or per capita allocation or by
any other method of allocation which does not take account of the equitable considerations referred
to in Section 5.8(b).

SECTION VI. MISCELLANEOUS PROVISIONS

     6.1. Reliance. Each of the parties hereto agrees that each covenant and agreement made by it
in this Agreement or in any certificate, instrument or other document delivered pursuant to this
Agreement is material, shall be deemed to have been relied upon by the other parties and shall
remain operative and in full force and effect after the date hereof regardless of any investigation
by any other party. This Agreement shall not be construed to confer any right or benefit upon any
Person other than the parties hereto and their respective successors and permitted assigns to the
extent contemplated herein.

     6.2. Legend on Securities. The Company and the Shareholders acknowledge and agree that in
addition to any other legend on the certificates representing Shares that may be held by them,
substantially the following legend shall be typed on each certificate evidencing any of the Shares
held at any time by any of the Shareholders:

THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO THE PROVISIONS OF A CERTAIN SHAREHOLDERS
AGREEMENT, DATED AS OF MARCH  _, 2006, INCLUDING CERTAIN RESTRICTIONS ON TRANSFER SET FORTH
THEREIN. A COMPLETE AND CORRECT COPY OF SUCH AGREEMENT IS AVAILABLE FOR INSPECTION AT THE PRINCIPAL
OFFICE OF THE COMPANY AND WILL BE FURNISHED UPON WRITTEN REQUEST AND WITHOUT CHARGE.

15

 

     6.3. Amendment and Waiver; Actions of the Board. Any party may waive in writing any provision
hereof intended for its benefit. No failure or delay on the part of any party hereto in exercising
any right, power or remedy hereunder shall operate as a waiver thereof. The remedies provided for
herein are cumulative and are not exclusive of any remedies that may be available to any party
hereto at law or in equity or otherwise. This Agreement may be amended with the prior written
consent of the Company and a Majority Interest; provided, however, that any such amendment that
adversely affects the Shareholders or Key Shareholders in a manner different than such Majority
Interest shall require a prior written consent of a majority-in-interest of the Shareholders or Key
Shareholders, as the case may be (in each case, based upon the number of Shares held thereby). Any
consent given as provided in the preceding sentence shall be binding on all Shareholders and
Investors.

     6.4. Notices. All notices, requests, demands and other communications provided for hereunder
shall be in writing and mailed (by first class registered or certified mail, postage prepaid),
telegraphed, sent by express overnight courier service or electronic facsimile transmission (with a
copy by mail), or delivered to the applicable party at the addresses indicated below:

     If to the Company:

Alma Lasers Ltd.

7 Haeshel Street P.O.B 3021

Caesarea Industrial Park 

Caesarea, Israel 38900 

Facsimile: 972-4-627-5368

Attention: Chief Executive Officer

     If to the Investors:

c/o TA Associates, Inc.

125 High Street, Suite 2500

Boston, MA 02110

Facsimile: (617) 574-6728

Attention: David S.B. Lang

     with a copy to:

c/o TA Associates, Ltd. 25

Buckingham Gate 

London SW1E 6LD, England 

Facsimile: 44-20-7932-2109

Attention: Ajit Nedungadi

     If to a Shareholder:

At such Person’s address for notice as set forth in on the signature

pages hereto:

16

 

Or, to each of the foregoing, at the address recorded in the Shareholders Register of the
Company, or by sending it to the facsimile recorded in the Shareholders Register of the Company,
and such notice shall be effective (i) if mailed, five (5) business days (and seven (7) business
days for international mail) after mailing, (ii) if sent by messenger, upon delivery, (iii) if sent
via telecopier, upon transmission and electronic confirmation of receipt or (if transmitted and
received on a non-business day) on the first business day following transmission and electronic
confirmation of receipt (provided however that any notice change of address shall only be valid
upon receipt), and (iv) one (1) business day (and three (3) business days for international mail)
after the business day of deposit with Federal Express or similar overnight courier, freight
prepaid.

     6.5. Headings. The section headings used or contained in this Agreement are for convenience of
reference only and shall not affect the construction of this Agreement. The parties have
participated jointly in the negotiation and drafting of this Agreement and the other agreements,
documents and instruments executed and delivered in connection herewith with counsel sophisticated
in investment transactions. If an ambiguity or question of intent or interpretation arises, this
Agreement and the agreements, documents and instruments executed and delivered in connection
herewith shall be construed as if drafted jointly by the parties and no presumption or burden of
proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions
of this Agreement and the agreements, documents and instruments executed and delivered in
connection herewith.

     6.6. Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     6.7. Remedies; Severability. It is specifically understood and agreed that any breach of the
provisions of this Agreement by any Person subject hereto will result in irreparable injury t o the
other parties hereto, that the remedy at law alone will be an inadequate remedy for such breach,
and that, in addition to any other legal or equitable remedies which they may have, such other
parties may enforce their respective rights by actions for specific performance (to the extent
permitted by law) and the Company may refuse to recognize any unauthorized Transferee as one of its
Shareholders for any purpose, including, without limitation, for purposes of dividend and voting
rights, until the relevant party or parties have complied with all applicable provisions of this
Agreement.

     If one or more of the provisions contained herein, or the application thereof in any
circumstances, is held invalid, illegal or unenforceable in any respect for any reason by a court
of competent jurisdiction, the validity, legality and enforceability of any such provision in every
other respect and of the remaining provisions contained herein shall not be in any way impaired
thereby, it being intended that all of the rights and privileges of the parties hereto shall be
enforceable to the fullest extent permitted by law.

     6.8. Entire Agreement. This Agreement is intended by the parties as a final expression of
their agreement and intended to be complete and exclusive statement of the agreement and
understanding of the parties hereto in respect of the subject matter contained herein.

17

 

     6.9. Adjustments. All references to share prices and amounts herein shall be equitably
adjusted to reflect share splits, share dividends, recapitalizations and similar changes affecting
the share capital of the Company.

     6.10. Law Governing. This Agreement shall be construed and enforced in accordance with and
governed by the laws of Commonwealth of Massachusetts (without giving effect to principles of
conflicts of law).

     6.11. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of
the respective successors and permitted assigns of the parties hereto as contemplated herein, and
any successor to the Company by way of merger or otherwise shall specifically agree to be bound by
the terms hereof as a condition of such succession. The rights of the Investors and the Key
Shareholders hereunder shall be binding upon and inure to the benefit of their Transferees of their
Securities as contemplated herein. This Agreement may not be assigned by any Shareholder except as
provided herein without the prior written consent of the Company and a Majority Interest, and
without such prior written consent any attempted assignment shall be null and void; provided,
however, that no such consent shall be required for assignments effected i n connection with a
Transfer in connection with which such Shareholder has complied with Section III.

     6.12. Dispute Resolution. All disputes, claims, or controversies arising out of or relating to
this Agreement, or any other agreement executed and delivered pursuant to this Agreement, or the
negotiation, validity or performance hereof and thereof or the transactions contemplated hereby or
thereby, that are not resolved by mutual agreement shall be resolved in accordance with the
provisions set forth in Sections 8.7 and 8.8 of the Purchase Agreement.

     6.13. Termination. Sections III, IV, V and VI shall terminate upon the Initial Public
Offering; provided, that the covenants set forth in Section 5.4 and Section 5.5 hereof shall
continue for so long as any Investor Nominee is a member of the Board of Directors, and the
covenants set forth in Section 5.9 hereof shall continue for so long as any Investor holds any
Shares or until the expiration of the applicable statute of limitations, if later.

     6.14. Shareholder Lock-Up. Each Shareholder and Investor hereby agrees, if so requested by the
Company and an underwriter of the Company’s share capital in connection with any public offering of
the Company, not to directly or indirectly offer, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any option, right or warrant
for the sale of or otherwise dispose of or transfer any shares held by it for such period, not to
exceed (a) one hundred eighty (180) days following the consummation of the Company’s initial public
offering of Ordinary Share or (b) ninety (90) days following the consummation of any other public
offering of Ordinary Share, as such underwriter shall specify reasonably and in good faith.

[SIGNATURE PAGE FOLLOWS]

18

 

     IN WITNESS WHEREOF, the parties hereto have caused this Shareholders Agreement to be duly
executed as of the date first set forth above.

	 	 	 	 	 	 	 
	THE COMPANY:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	ALMA LASERS LTD.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Ziv Karni	 	 
	 

	 	 	 	 

Name:
	 	 
	 

	 	 	 	Title:	 	 
	 
	 	 	 	 	 	 
	SHAREHOLDERS:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 

	 	 	 	 	 	 	 
	/s/ Ziv Karni
 

Dr. Ziv Karni

	 	 	 	/s/ Yoav Avni
 

Yoav Avni
	 	 
	 
	 	 	 	 	 	 
	Address:

	 	 	 	Address:	 	 
	c/o Alma Lasers Ltd.

	 	 	 	c/o Alma Lasers Ltd.	 	 
	Haeshel 7

	 	 	 	Haeshel 7	 	 
	Caesarea Industrial Zone

	 	 	 	Caesarea Industrial Zone	 	 
	Caesarea 38900, Israel

	 	 	 	Caesarea 38900, Israel	 	 
	 
	 	 	 	 	 	 
	/s/ Nadav Bayer

	 	 	 	/s/ Yevgeni Kodritzki	 	 
	 

Nadav Bayer

	 	 	 	 

Yevgeni Kodritzki
	 	 
	 
	 	 	 	 	 	 
	Address:

	 	 	 	Address:	 	 
	c/o Alma Lasers Ltd.

	 	 	 	6 Arisaig Drive	 	 
	Haeshel
7

	 	 	 	Maple, Ontario L6A 1V6	 	 
	Caesarea Industrial Zone

	 	 	 	Canada	 	 
	Caesarea 38900, Israel
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	/s/ HB
 

Global Healthcare Services

	 	 	 	/s/ [ILLEGIBLE]
 

Lahav,
Litbak, Abadi, Adv.
	 	 
	 
	 	 	 	 	 	 
	by

	 	 	 	by Masada Litbak, Abadi, Adv., Partner	 	 
	 
	 	 	 	 	 	 
	title

	 	 	 	title partner	 	 
	 
	 	 	 	 	 	 
	Address:

	 	 	 	Address:	 	 
	c/o Hillel Bachrach

	 	 	 	52 Menachem Begin Road	 	 
	20/20 Healthcare Partners LLC

	 	 	 	Sonol Tower, 21st floor	 	 
	2000 Commonwealth Ave.

	 	 	 	Tel Aviv 67137, Israel	 	 
	Auburndale, MA 02466
	 	 	 	 	 	 
	USA
	 	 	 	 	 	 

 

 

	 	 	 	 	 	 	 
	/s/ Amit Wjuniski
 

Oxford Investment Overseas Corp

	 	 	 	/s/ HB 

Antonio Saclemente Garcia	 	 
	 
	 	 	 	 	 	 
	by Amit Wjuniski
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	title
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Address:
	 	 	 	Address:	 	 
	c/o Alma Lasers Inc
	 	 	 	c/o Hillel Bachrach	 	 
	6556 NW 9th Avenue, Suite 303
	 	 	 	20/20 Healthcare Partners LLC	 	 
	Fort Lauderdale, Florida 33309
	 	 	 	Aubumdale, MA 02466	 	 
	USA
	 	 	 	USA	 	 
	 
	 	 	 	 	 	 
	/s/ Mauro Wjuniski 

Damsi Investment, LLC
	 	 	 	/s/ HB 
Myriam Patricia Vinasco	 	 
	 
	 	 	 	Address:	 	 
	 
	 	 	 	 	 	 
	by Mauro Wjuniski
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	title
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Address:
	 	 	 	Address:	 	 
	c/o Alma Lasers Inc
	 	 	 	c/o Hillel Bachrach	 	 
	6556 NW 9th Avenue, Suite 303
	 	 	 	20/20 Healthcare Partners LLC	 	 
	Fort Lauderdale, Florida 33309
	 	 	 	Aubumdale, MA 02466	 	 
	USA
	 	 	 	USA	 	 
	 
	 	 	 	 	 	 
	/s/ Yariv Matzliach
	 	 	 	/s/ Mauro Wjuniski	 	 
	 
	 	 	 	 	 	 
	Yariv Matzliach
	 	 	 	Mauro Wjuniski	 	 
	 
	 	 	 	 	 	 
	Address:
	 	 	 	Address:	 	 
	c/o Alma Lasers Inc
	 	 	 	c/o Alma Lasers Inc	 	 
	6556 NW 9th Avenue, Suite 303
	 	 	 	6556 NW 9th Avenue, Suite 303	 	 
	Fort Lauderdale, Florida 33309
	 	 	 	Fort Lauderdale, Florida 33309	 	 
	USA
	 	 	 	USA	 	 

 

 

INVESTORS:

	 	 	 	 	 
	 	AESTHETIC ACQUISITION B.V.

 	 
	 	By:  	/s/ Ajit Nedungadi
	 
	 	 	Name:  	Ajit Nedungadi

 	 
	 	and
 	 
	 	 	 
	 	By:  	
 	 
	 	 	Name:  	 	 
	 

[Signature Page to Shareholders Agreement]

 

 

INVESTORS:

	 	 	 	 	 
	 	AESTHETIC ACQUISITION B.V.

 	 
	 	By:  	/s/ J.J. Van Ginkel
 	 
	 	 	Name:  	 	 
	 
	 	and
 	 
	 
	 	By:  	
 	 
	 	 	Name:  	 	 
	 	 	 	 
	 

[Signature Page to Shareholders Agreement]

 

 

EXHIBIT A

Form of Joinder Agreement

     The undersigned hereby agrees,
effective as of the date hereof, to become a party to that
certain Shareholders Agreement (the “Agreement”) dated as of March      
               , 2006, by and among
[                  
                  
     ] (the “Company”) and the parties named therein and for all purposes
of the Agreement, the undersigned shall be included within the term
[“Shareholder”/“Investor”] (as defined in the
Agreement), and to be bound by the Articles of Association of the Company. The undersigned further
confirms that the representations and warranties contained in Section II of the Agreement are true
and correct as to the undersigned as of the date hereof. The address and facsimile number to which
notices may be sent to the undersigned is as follows:

	 	 	 	 	 	 	 	 	 
	Facsimile No.
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 

[NAME OF UNDERSIGNED]
	 	 

1

 

EXHIBIT B

Form of Employee Nondisclosure, Noncompetition and Assignment Agreement

2

 

SCHEDULE A

Shareholders and Investors

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]